The molecular mechanisms underlying constitutive nuclear factor-jB (NF-jB) activation in solid tumors has not been elucidated. We show that Annexin-1 (ANXA1) is involved in this process, and suppression of ANXA1 in highly metastatic breast cancer cells impedes migration and metastasis capabilities in vitro and in vivo. ANXA1 expression correlates with NF-jB activity, suggesting that ANXA1 may be required for the constitutive activity of IjB kinase (IKK) and NF-jB in highly metatstatic breast cancer. Gel-filtration analysis demonstrated that ANXA1 co-elutes with the members of the IKK complex and NF-jB signaling pathway, and immunoprecipitation confirmed that ANXA1 can bind to and interact with IKKc or NEMO, but not IKKa or IKKb. Importantly, silencing of ANXA1 prevents the interaction of NEMO and RIP1, which indicates that ANXA1 is required for the recruitment of RIP1 to the IKK complex, which may be important for the activation of NF-jB. Downstream targets of NF-jB include uPA and CXCR4, which can be modulated by ANXA1 silencing. CXCR4-mediated migration of breast cancer cell lines in response to CXCL12 was significantly modulated by ANXA1, indicating its importance in the tissue-specific migration of breast cancer cells. Chromatin immunoprecipitation experiments confirmed that in ANXA1 overexpressed cells, NF-jB was recruited to CXCR4 promoter without external stimulation, indicating that ANXA1 is critical for the constitutive activation of NF-jB in breast cancer to promote metastasis. Finally, we show that ANXA1 overexpression enhances metastasis and reduces survival in an intracardiac metastasis model, while ANXA1-deficient mice crossed with MMTV-PyMT mice display significantly less metastasis than their heterozygous littermates, indicating that ANXA1 is an important gene in breast cancer metastasis. Our data reveal that ANXA1 can constitutively activate NF-jB in breast cancer cells through the interaction with the IKK complex, and suggests that modulating ANXA1 levels has therapeutic potential to suppress breast cancer metastasis.
Introduction
The nuclear factor-kB (NF-kB) family of eukaryotic transcription factors is comprised of several structurally related proteins that form homodimers and heterodimers characterized by the highly conserved DNAbinding/dimerization domain called the Rel homology region (Hayden and Ghosh, 2004) . The most common Rel/NF-kB dimer in mammals contains p50-RelA and is specially termed NF-kB. Binding of NF-kB to IkB sequesters the complex in the cytoplasm, maintaining NF-kB in an inactive state, preventing translocation to the nucleus. IkB is activated by the IkB kinase (IKK) complex, consisting of IKKa, b and g (or NEMO). The activation of NF-kB in normal cells is inducible, which prevents abnormal cell growth and survival. However, in cancer, constitutive activation of NF-kB is observed (Ghosh and Karin, 2002) . The constitutive activation of NF-kB in lymphoid cancer is thought to be caused by mutations of multiple genes (Keats et al., 2007) . However, the molecular mechanisms that result in the constitutive activation of NF-kB in solid tumors is unclear .
The annexin superfamily of calcium and phospholipid-binding proteins has been implicated in many cellular processes, including differentiation, apoptosis, proliferation and inflammation. In particular, Annexin-1 (ANXA1) is anti-inflammatory, anti-proliferative and pro-apoptotic, and regulates differentiation (Flower and Rothwell, 1994; Perretti and Gavins, 2003; Parente and Solito, 2004; Lim and Pervaiz, 2007) . The expression of ANXA1 has been studied in many types of cancer; however, there is no consensus on the role of this protein in tumor initiation and/or progression. ANXA1 has been reported to be reduced or lost in many cancers (Lim and Pervaiz, 2007) . In breast cancer, however, reports are conflicting, where ANXA1 expression has been shown to be increased in some ductal carcinomas (Ahn et al., 1997; Pencil and Toth, 1998 ), but we and others have recently reported a loss of ANXA1 in breast carcinomas (Shen et al., 2006; Cao et al., 2008; Ang et al., 2009) . Interestingly, ANXA1 was higher in metastatic tumors and lymph nodes compared with primary tumors (Shen et al., 2006) , and ANXA1 is often identified as a metastatic biomarker in highly metastatic breast cell lines (Cicek et al., 2004; Kreunin et al., 2007) . Of importance, ANXA1 has been shown to activate NF-kB in T cells and T cells from ANXA1-deficient mice exhibited decreased NF-kB activation, indicating that ANXA1 may somehow regulate NF-kB. However, the mechanism behind this regulation has not been addressed.
As NF-kB becomes strongly activated as breast cancer cells progress to a more aggressive, chemoresistant and estrogen-independent status and ANXA1 expression is found to be higher in metastatic tumors and lymph nodes than in the primary tumor, we hypothesize that ANXA1 may have a prominent role in breast cancer metastasis, through the regulation of NF-kB.
Results
NF-kB is constitutively activated in many aggressive and metastatic tumors and tumor cell lines including MDA-MB-231 cells (MDA-231, estrogen-receptor a negative, highly invasive) and is implicated in this progression (Patel et al., 2000) . Interestingly, low levels of ANXA1 were observed in MCF7 and T47D (estrogen receptor a positive, lowly invasive) as compared with MDA-231 cells (Figure 1a) . This links the expression of ANXA1 to the progression of breast cancer from a hormone-dependent, nonmetastatic, anti-estrogen-sensitive phenotype, to a hormone-independent, anti-estrogen-and chemotherapy-resistant phenotype, with highly invasive and metastatic growth properties (Nakshatri et al., 1997) . Interestingly, ANXA1 expression levels correlated closely with NF-kB activity in these cell lines (Figure 1b) , as well as migration capability (Supplementary Figure S1c ). We next investigated if ANXA1 could modulate the NF-kB pathway in our model. MCF7 breast cancer cells expressing low levels of endogenous ANXA1 were stably transfected to express either an empty vector (pcDNA3.1-V5 or MCF7-EV), or ANXA1-expressing plasmid (pcDNA3.1-ANXA1-V5 or MCF7-V5; Supplementary Figures S1a and b) . Enforced expression of ANXA1 in MCF7-V5 cells increased NF-kB activity, comparable to that of MDA-231 cells (Figure 1c ). MCF7-V5 cells exhibited significantly higher NF-kB DNA binding, while silencing of ANXA1 in MDA-231 cells decreased NF-kB DNA binding. In addition, MCF7-V5 cells induced (Figure 1d ), while silencing of ANXA1 in MDA-231 cells decreased IkBa phosphorylation and degradation, signifying a crucial role of ANXA1 in NF-kB signaling.
The canonical pathway of NF-kB activation takes place through the activation of IKK complex, which is the focal point of convergence of most stimuli activating NF-kB including TNF-a (Patel et al., 2000) . Treatment of MDA-231 cells with TNF-a induced IkBa phosphorylation (Figure 1e ), while cells co-treated with ANXA1 anti-sense oligonucleotide (ASO) (Supplementary Figure S1e) exhibited no IkBa activation. These results indicate that ANXA1 might be acting upstream of IkBa. We next determined if ANXA1 could mediate IKK activation, which phosphorylates IkBa. A dose-dependent increase in IKK phosphorylation was observed when ANXA1 was transiently overexpressed (Figure 1f ), while silencing of ANXA1 inhibited IKK phosphorylation after TNF-a treatment (Figure 1e ), suggesting that ANXA1 targets the IKK complex to regulate NF-kB. Increased NF-kB p65-Ser536 phosphorylation is considered to be another important step for NF-kB transactivation (Sakurai et al., 1999) . NF-kB p65 was phosphorylated after TNF-a treatment in MDA-231 cells with no change in corresponding protein levels, while this was not observed in ANXA1-ASO-treated MDA-231 cells, indicating that this might be another way by which ANXA1 regulates NF-kB.
The IKK complex is a giant complex of B700-900 kDa. The IKK complex is composed of the IKK proteins, and several other adaptor proteins complexes (Chen et al., 2002) . To determine whether ANXA1 associates with the IKK complex, lysates from MCF7-EV, MCF7-V5 and MDA-231 cells were subjected to gel-filtration chromatography followed by western blot analysis of the fractions with antibodies against phospho-IKKa, IKKb, NEMO, receptor interacting protein (RIP), ANXA1, TAK1, TRADD (TNF receptor-1-associated death domain protein) and p52 antibodies. We collected void volume that is represented as fraction number 1, and immediately after void volume, the fractions 5-12, respectively. Our results are consistent with the previous findings that IKK complex exists as an B700-900 kDa protein complex (Wetterwald et al., 2002) . Analysis of MCF7-EV and MCF7-V5 cells showed IKK phosphorylation in a prominent pool with a relative molecular mass (Mr) of B700 kDa (fractions 7-9) in MCF7-V5 cells, but not in MCF7-EV cells (Figure 2a) . Analysis of MCF7-V5 cells showed that ANXA1 is also highly detectable in fractions 7-9 ( Figure 2c ). However, in MDA-231 cells, ANXA1 was detected both in high molecular (B700-900 kDa) and low molecular weight (B300 kDa) complexes (Figure 2d ). Analysis of MCF7-V5 cells showed that NEMO is detectable in high molecular weight complex in fractions 6-9 (Figure 2c ), but not in smaller fractions (10) (11) (12) , when compared with MCF7-EV (Figure 2b) , where NEMO elutes out in every fraction. MCF7-V5 cells showed another high molecular weight band B100 kDa. Analysis of MCF7-V5 cells showed that RIP is detectable in high and small molecular weight complexes, more prominent in fractions 7-9 (Figure 2c ), when compared with MCF7-EV cells. RIP exhibited a high molecular size of B150 kDa band in MCF7-V5 cells. Once again, as evident from Figure 2a , MCF7-V5 fractions demonstrated increased IKK phosphorylation levels. This suggests that ANXA1 overexpression may enforce NEMO and RIP oligomerization, resulting in activation of IKK complex. This is in agreement with previous studies showing that enforced oligomerization of RIP, NEMO, IKKa, IKKb is sufficient for inducing IKK activation (Poyet et al., 2000) . In addition, TRADD was found in smaller molecular weight fractions, while TAK1 was found in higher fractions in MCF7-V5 cells. No differences were seen in IKKa, IKKb and p100/p52 fractions when ANXA1 was overexpressed (Supplementary Figure S2) . Notably, the differences between MCF7 and MDA-231 cells were very distinct, where p100/p52, were eluted in much larger molecular weight fractions, indicating constitutive expression of the alternative NF-kB pathway in MDA-231 cells as well. We further verified gel-filtration purified fractions for ANXA1 association with NEMO by immunoprecipitation. NEMO co-precipitated with ANXA1 in fractions 7-9 ( Figure 2e , upper panel) in MCF7-V5 cells but not in MCF7-EV cells. To further confirm, the same membrane was probed for ANXA1 antibody, and we found that ANXA1 was detected in the same fractions as NEMO (fractions 7-9) in MCF7-V5 cells (Figure 2e , lower panel). This indicates that ANXA1 co-elutes and precipitates in the same fraction as NEMO.
To determine whether ANXA1 directly binds to NEMO and RIP, we co-transfected ANXA1 and IKKa or IKKb, NEMO or RIP overexpressing plasmids into MCF7 cells. We found that ANXA1 physically associates with NEMO and RIP (Figure 3a ), but not IKKa or IKKb. Since MDA-231 endogenously expresses high levels of ANXA1, NEMO and RIP, we confirmed these results in MDA-231 cells (Figure 3b ). Indeed, NEMO and RIP associated with ANXA1 in MDA-231 cells. Our findings suggest that ANXA1 is an endogenous binding partner of NEMO and RIP, which may induce a Figure 3c shows that when ANXA1 is silenced, the interaction between NEMO and RIP is disrupted, indicating that this disruption may lead to inactivation of NF-kB. To examine if ANXA1 may also associate with NF-kB p65 to regulate its activity, as indicated by Zhang et al. immunoprecipitation was performed ( Figure 3d ). We observed that ANXA1 can interact with p65 subunit of NF-kB in MCF7-V5 cells. Furthermore, silencing of ANXA1 in MCF7-V5 cells using ANXA1 ASO resulted in a decrease in the interaction between ANXA1 and p65, indicating another mechanism through which ANXA1 can regulate NF-kB. Next, we asked if ANXA1 could co-localize with NEMO or RIP1. Confocal imaging showed high levels of ANXA1 and NEMO co-localized in the cytoplasm of MDA-231 cells ( Figure 3e ). Interestingly, NEMO was observed in the nucleus of MDA-231 cells, while ANXA1 was not. Similarly, endogenous co-localization of ANXA1 and RIP1 was observed in the cytoplasm of MDA-231 breast cancer cells (Figure 3f ). This illustrates that ANXA1 can be found in the same cellular compartment as NEMO and RIP1, which could facilitate their interaction.
To investigate if ANXA1 expression could modulate metastasis in vivo, MCF7 cells, which are normally nonmetastatic breast cancer cells, were injected into estrogen-supplemented nu/nu athymic mice via an intracardiac injection. Mice injected with EV-transfected MCF7 cells exhibited prolonged survival, while mice injected with MCF7 cells overexpressing ANXA1 survived significantly less (P ¼ 0.0022), with a median survival time of 36 days ( Figure 4a ). This decrease in survival was not due to increased tumor load, as these same cells were also xenografted in mammary pads of estrogen-supplemented nu/nu athymic mice and tumor volumes were measured (Supplementary Figure S3a) . No significant difference in tumor growth rates were observed up to 6 weeks after the xenograft. These results show that ANXA1 may be functionally involved in tumor metastasis. As this model does not extend to physical demonstration of pulmonary metastasis, we crossed ANXA1-deficient (ANXA1 À/À ) mice with spontaneous breast cancer mice (MMTV-PyMT) ( Figure 4b Annexin-1 constitutively activates NF-jB P Bist et al
Several genes have been extensively implicated in the regulation of metastasis, such as uPA (Mukhina et al., 2000) and CXCR4 (Muller et al., 2001) . ANXA1 overexpression upregulated uPA mRNA expression in MCF7 cells (Figure 5a ) and silencing of ANXA1 in MDA-231 cells significantly decreased TNF-a-mediated upregulation of uPA (Figure 5b) . Similarly, ANXA1 regulates cellular protein levels ( Figure 5c ) and surface expression (Figure 5d ) of CXCR4 in breast cancer cells. This indicates that ANXA1 is required for the transcription of uPA and CXCR4, which are both NF-kB responsive genes. To further investigate the role of ANXA1 in the regulation of breast cancer migration, we focused our efforts on CXCR4. Specific expression of CXCR4 on breast cancer cells critically leads to metastasis of these tumor cells towards SDF1a (stromal-derived factor 1 a, also known as CXCL12), to organs historically known to be sites of breast metastasis, such as bone and lung (Muller et al., 2001 ). SDF1a was not effective in inducing migration of MCF7 cells, which express low levels of CXCR4, while it induced a concentration-dependent migration of MDA-231 cells to an optimal concentration of 100 ng/ml (Figure 5e ). At concentrations 4100 ng/ml, migration rates fell, which may be due to receptor internalization. Overexpression of ANXA1 exhibited significantly increased migration Abbreviation: ANXA1, Annexin-1. Age of onset and tumor numbers were not different in both groups, while metastasis incidence was less in ANXA1 À/À mice. were analyzed for migration ability to SDF1a (100 ng/ml). Data are represented as mean ± s.e.m. of triplicate determinations, and comparisons within individual cell lines were made using the Student's two-tailed t-test. **P ¼ 3.4 Â 10 À5 vs EV-transfected cells, ***P ¼ 2.04 Â 10 À8 vs mock-transfected cells.
MDA-MB-
Annexin-1 constitutively activates NF-jB P Bist et al to SDF1a treatment (Figure 5f , upper panel). Notably, SDF1a-induced migration was greatly decreased in ANXA1-depleted MDA-231 cells (Figure 5f , lower panel). These results suggest that ANXA1 may have critical roles in tumor migration and metastasis by upregulating CXCR4 expression, modulating the sensitivity of breast tumor cells to directional migration towards SDF1a. SDF1a is thought to recruit primary tumors to metastatic sites by inducing additional CXCR4 expression via NF-kB activation (Kukreja et al., 2005) . Next, we examined whether ANXA1 modulated SDF1a/NFkB-induced cancer cell migration. In a wound healing assay ( Figure 6a ) and transwell migration assay (Figure 6b ), MCF7-V5 cells exhibited significantly faster migration as compared with MCF7 cells, and this was inhibited more significantly upon pre-treatment with an NF-kB inhibitor BAY11-7082. We next determined whether ANXA1 is associated with activation of the NF-kB p65 transcription function by SDF1a. Cells were transfected with a construct harboring an NF-kB-binding site upstream of the luciferase reporter following SDF1a treatment. ANXA1 expression was associated with activation of NF-kB transcriptional activity (Figures 6c and d) . This suggests that ANXA1 is required for SDF1a-induced NF-kB signaling. BAY11-7082 inhibited CXCR4 mRNA expression in MDA-231 cells (Figure 6e ), indicating that CXCR4 expression is NF-kB dependent. Finally, to determine the regulatory circuit responsible for ANXA1-mediated CXCR4 expression, in vivo NF-kB activation was examined by chromatin immunoprecipitation. NF-kB was recruited to CXCR4 promoter following SDF1a treatment in MCF7 cells (Figure 6f) . Notably, NF-kB was recruited to CXCR4 promoter in MCF7-V5 cells without SDF1a treatment. In contrast, silencing of ANXA1 in MCF7-V5 cells reduced NF-kB recruitment to the CXCR4 promoter in basal as well as SDF1a stimulated cells (Figure 6g ). We further confirmed these results by electrophoretic mobility shift assay. We found that NF-kB DNA binding was increased in MCF7-V5 cells following SDF1a treatment, sustained up to 1 h (Supplementary Figure S2e) , while silencing of ANXA1 in MCF7-V5 cells decreased NF-kB DNA binding following SDF1a treatment. This proves that ANXA1 is involved in NF-kB recruitment to the CXCR4 promoter. Taken together, these results reveal a physiological and possibly critical role for ANXA1 in the constitutive activation of NF-kB in breast cancer cells through the binding and modulation of IKK activity, and that ANXA1-regulated NF-kB signaling is necessary for SDF1a/CXCR4 axis in breast cancer cell migration and metastasis (Figure 7) . Annexin-1 constitutively activates NF-jB P Bist et al
Discussion
Constitutive activation of NF-kB is observed during breast cancer progression to a malignant phenotype with high invasive and metastatic growth properties (Nakshatri and Goulet, 2002) . We have explored the regulatory mechanism of the constitutive activation of NF-kB in breast cancer cells, and our results show that ANXA1 is one factor which may be responsible for aberrant activity of NF-kB in breast cancer cells. Silencing of ANXA1 in highly metastatic MDA-231 cells inhibited constitutive NF-kB activation, resulting in reduced IKK, IkBa and p65 phosphorylation. We did not observe apoptosis in cells depleted with ANXA1 following TNF-a treatment, suggesting that the small quantity of NF-kB present may be functional and required for basal activity. These results are consistent with previous studies, demonstrating that NF-kB activation does little to alter apoptosis index of MDA-231 cells (Monks and Pardee, 2006) . We, for the first time, partially purified IKK complexes from MCF7, MCF7-V5 and MDA-231 breast cancer cells and found that ANXA1 overexpression resulted in activation of NEMO and RIP. This is in line with the study conducted by Ea et al. that reported NEMO, RIP, IKKa, IKKb overexpression resulted in IKK activation. NEMO contains two coiled-coil motifs, a leucine zipper, a C-terminal zinc-finger domain (Ea et al., 2006) . These two domains are necessary for the correct assembly of the IKK complex (Palkowitsch et al., 2008) , and for the recruitment of upstream molecules, whose interaction with NEMO is essential for the IKK-mediated NF-kB activation. In addition to the physical interaction of NEMO with upstream molecules, a novel mechanism of IKK recruitment and activation is linked to the ability of NEMO to recognize polyubiquitinated signaling intermediates, such as RIP (Ea et al., 2006) . This activity is necessary for NF-kB activation in numerous signaling pathways, such as TNFR, IL1R/TLR or TCR. Upon stimulation, K63-linked polyubiquitination of downstream molecules such as RIP promotes the binding of NEMO to these molecules, thus determining the recruitment and activation of the IKK complex. Our immunoprecipitation results demonstrated that ANXA1 interacts with both NEMO and RIP. This interaction might be a key mechanism for constitutive activation of NF-kB during tumorigenesis and metastasis. It is possible that besides binding to IKK component, ANXA1 has the ability to interact with components of several other signaling pathways, and thereby, acting as a crosstalk messenger. NEMO is an integral component of IKK complex, and phosphorylation of NEMO leads to a conformational change, which allows the access of phosphatases that subsequently decrease IKK activity (Palkowitsch et al., 2008) . It is quite possible that in cells overexpressing ANXA1, phosphatases may not have access to NEMO, and NF-kB activation remains indefinitely active. The ubiquitin-proteosome pathway has distinct roles in NF-kB pathway in modulating the intensity, timing and diversity of the inflammatory response, and in the generation of the IKK complex, which critically Figure 7 A proposed model depicting the effects of ANXA1 in the regulation of NF-kB activation and metastasis through interactions with NEMO and RIP. In normal cells or tumor cells that express low levels of ANXA1, the IKK complex normally regulates IkB activation and phosphorylation, which in turn regulates NF-kB activity, which upon phosphorylation of IkB, dissociates and translocates to the nucleus for transcriptional activity. Transcription of newly formed IkB sequesters NF-kB from the nucleus to stop transcription. In metastatic tumor cells that express high levels of ANXA1, ANXA1 interacts with NEMO and RIP1 in a complex and stabilizes the IKK complex, resulting in high levels of phosphorylated IkB, and constitutively active NF-kB. A full colour version of this figure is available at the Oncogene journal online.
Annexin-1 constitutively activates NF-jB P Bist et al regulates the association of IkBa with the p50/p65 complex. IKK is activated following engagement of cell surface receptors such as TNF-a binding to TNF receptor. This leads to the recruitment of TRADD, which then recruits TRAF2 (TNF receptor-associated factor 2), and thereafter the RIP. This quaternary complex activates the E3 ligase activity of TRAF2. Activated TRAF2 catalyzes its own polyubiquitination, is released into the cytoplasm and subsequently polyubiquitinates RIP. Ubiquitinated RIP is recognized by the IKK trimeric complex and promotes the phosphorylation and activation of IKK, which will phosphorylate IkBa. RIP is polyubiquitinated via ubiquitin's internal Lys 63 to promote signaling, as well as via Lys 48 linkages, which target RIP to proteasomal degradation. Similar to its role in TNF receptor signaling, the ubiquitination of TRAF6, a mediator of interleukin 1 receptor action, also promotes the phosphorylation and activation of IKK. There is every possibility that ANXA1 may stabilize NEMO and RIP by a ubiquitin-mediated process. Further studies are in progress to rule out such possibilities.
Although a number of signaling mechanisms have been implicated in facilitating the dispersal of cancer, there has been a growing recognition that this process is a selective process governed by directional migratory cues (Strieter, 2001 ). Chemokines and their receptors have recently been shown to be important for cell migration and invasion in various cancers (Balkwill, 2004) . Chemokine receptors, including CXCR4 have a critical role in metastasis, and that CXCR4, in particular, is a key receptor in the crosstalk between tumor cells and their environment (Burger and Kipps, 2006) . CXCR4 expression increases progressively with increasing malignant potential, and higher expression is associated with lymph node positivity, hormone receptor negativity, Her2 overexpression and poor survival in breast cancer (Cabioglu et al., 2005; Mehta et al., 2007) , and that CXCR4 can act as a biomarker for metastasis (Cabioglu et al., 2005) . Interestingly, CXCR4 has been shown to be regulated by NF-kB (Palkowitsch et al., 2008) and p53 (Mehta et al., 2007) . Overexpression of DN-IkBa in breast cancer cells resulted in reduced expression of CXCR4, and a corresponding loss of SDF1a-mediated migration in vitro (Helbig et al., 2003) . In view of all these observations and our earlier findings that ANXA1 expression is upregulated in metastatic cancer cells, we have shown that ANXA1 regulates CXCR4 in an NF-kB-dependent manner. Modulation of NF-kB constitutive activation by ANXA1 will likely provide deeper insights and therapeutic opportunities for treating metastatic disease, a major problem that has remained largely intractable.
The present results provide support for a model (Figure 7 ) in which binding of ANXA1 to NEMO and RIP results in targeting NF-kB-p65 to the promoters of NF-kB target genes such as CXCR4 and uPA. In breast cancer cells overexpressing ANXA1, NF-kB occupancy of the CXCR4 NF-kB responsive element was constitutively detectable using chromatin immunoprecipitation. These findings and the demonstration that silencing ANXA1 attenuates activation of NF-kB indicates that ANXA1 can regulate the transcriptional function of NF-kB-p65. Zhang et al. (2010) reported that ANXA1 is induced by anti-inflammatory drugs and can associate with NF-kB-p65 and this complex negatively regulates NF-kB in colon and pancreatic cancer cells. We show in our study that ANXA1 is a positive regulator of NF-kB activity, and interacts with NF-kB-p65, as well as other upstream components of the NF-kB pathway. This difference may be due to celltype specificity or the status of ANXA1 expression in a particular cell. In addition, tissue specificity of drug mechanism may also differ. We have shown that ANXA1 and NF-kB are both endogenously and constitutively activated in MDA-231 cells, and this constitutive activation of ANXA1 and NF-kB as a complex contributes to a physiologic defence mechanism exploited by human cancer cells. As NF-kB is regulated at several signaling points, the first checkpoint is IKK signalosome, which is the main convergence focal point of several stimuli. Our pull-down assays clearly demonstrate that ANXA1 associates with one of the IKK components that is NEMO or IKKg, and not with IKKa or IKKb. Another protein of interest that interacted with ANXA1 was RIP, which has also been shown to interact with NEMO. This complex (NEMO-ANXA1-RIP) may promote a survival response by upregulating NF-kB.
Breast carcinomas that are positive for estrogen and progesterone receptors have been shown to be ANXA1 negative (Cao et al., 2008) , confirming previous reports that ANXA1 expression is lost in human breast cancer epithelial cells (Shen et al., 2005; Ang et al., 2009) . However, triple negative, or estrogen receptor, progesterone receptor and Her2/neu negative breast cancers were to be ANXA1 positive (Cao et al., 2008) . Very recently, ANXA1 was found highly expressed in basallike breast cancer, and possessed functional activity in regulating migration and mesenchymal-like phenotype, through the regulation of TGF-b/SMAD signaling (de Graauw et al., 2010) . This is complementary to our study, where we find similar phenotypic changes with regard to the regulation of metastasis, albeit through a different mechanism.
Our studies have laid down a novel and solid foundation for future studies aiming to reveal additional insights into the molecular mechanisms governing its role in breast cancer cell migration and invasion, and its interplay with other proteins involved in the development, progression and metastasis of breast cancer. As ANXA1 has an important role in the growth and invasiveness of basal-like breast cancer, it might prove to be an effective therapeutic target for basal-like breast cancer in particular.
Materials and methods

Cell culture
Human breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection 
Animals
All animal work was approved by the Institutional Animal Care and Use Committee and followed National Advisory Committee for Laboratory Animals Research. Nu/nu athymic mice (6-8 weeks) were obtained and housed in the Biopolis Research Centre, Singapore in pathogen-free conditions. Mice were kept on a 12-h light/dark cycle with food and water provided ad libitum. MCF7 cells were stably transfected with an expression vector against ANXA1, or EV. For the xenograft study, cells were injected in the left abdominal fat pad and mice were monitored for up to 40 days and tumors were palpated twice weekly. Tumor volume was calculated as (length Â width Â width/2). Mice were killed by anesthetic overdose either at the end of the study or earlier if they displayed significant weight loss, signs of distress or palpable tumors 42 cm in diameter. For the intracardiac metastasis study, 10 5 cells in 100 ml were injected via intracardiac injection and mice were monitored for up to 60 days, and survival rates were monitored and calculated using Kaplan-Meier analysis.
Transfection MDA-231 cells were seeded in six-well plates, and transiently double transfected with anti-sense phosphorothioate oligodeoxynucleotides (5 0 -GsTsTsGsAsCsGsCsTsGsTsGsCs AsTs TsGsTsTsT-3 0 ) (Sigma-Proligo, Singapore) using the SuperFect reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. A pCDNA3.1-V5-tagged plasmid expressing human ANXA1 was stably transfected into MCF7 cells using SuperFect reagent. ANXA1 was amplified by PCR using human peripheral blood mononuclear cells cDNA and PCR primers without the stop codon to clone in frame with the V5 tag at the COOH terminus. A control set of cells was transfected with an empty pcDNA3.1 (MCF7-EV).
Immunoprecipitation and immunoblotting
Cell lysates were prepared in 1 Â IP lysis buffer. Equal amount of lysate (300 mg) was incubated overnight with anti-ANXA1 or anti-NEMO, or anti-RIP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies and 20 ml Sepharose beads (Santa Cruz), and tumbled overnight in cold room. Immune complexes were eluted in 1 Â SDS-PAGE lading dye, vortexed and heated at 90 1C for 5 min. Immune complexes were subjected to immunoblot analysis. For western blot analysis, cells were scraped in the presence of a lysis buffer and supernatant was collected and stored at À80 1C until evaluation by SDS-PAGE analysis. Equal amounts of protein from each sample were subjected to 10% SDS-PAGE at a constant voltage of 125 V. The proteins were transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Proteins were determined by western blotting with specific antibodies, and expression signals were obtained by enhanced chemiluminescence. Protein expression was normalized to actin or tubulin levels.
Migration assays
Migration was assayed using 6.4 mm diameter cell culture inserts with 8 mm pore size polyethylene terephthalate membrane filters (BD Biosciences, San Jose, CA, USA) in 24-well tissue culture plates. Serum-starved cells were added to the upper chamber and serum-free media with DMEM supplemented with 10% fetal bovine serum or SDF1a (100 ng/ml) was added to the lower chamber and incubated for 16 h at 37 1C in 5% CO 2 . Cells were wiped from the top surface of the filter, and cells on the bottom surface were fixed and stained for counting.
Protein gel-filtration chromatography Cells were grown to 70% confluence, scraped in ice-cold 1 Â PBS. The cell lysates were lysed in Lysis buffer (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM sodium vandate, 1 mM dithiothreitol, 10 mM sodium fluoride) containing complete tablet protease inhibitor (Roche, Indianapolis, IN, USA) for 20 min on ice (with intermittent shaking at every 5 min interval). The cell lysates were cleared at 13 000 r.p.m. for 20 min. The supernatant was transferred into a fresh tube and quantitated using Bradford's reagent. Equal amount of cells (4 mg) were separated on Sepharose column (Sephacryl 200) using lysis buffer. Fifteen fractions of 2 ml each were collected and 30 ml aliquots were subjected to western blot analysis.
Chromatin immunoprecipitation
Cells were processed for the chromatin immunoprecipitation assay. The Ab used for the chromatin immunoprecipitation was NF-kB (p65) Ab (Cell Signaling, Danvers, MA, USA). The sequence for human CXCR4 gene promoter was follows: sense primer, 5 0 -ACAGAGAGACGCGTTCCTAG-3 0 and anti-sense primer, 5 0 -AGCCCAGGGGACCC TGCTG-3 0 . The PCR products were analyzed on 2% agarose gel electrophoresis and documented.
Electrophoretic mobility shift assay Nuclear extracts were prepared according to the manufacturer's instructions (Pierce, Rockford, IL, USA). The protein concentration was determined by Bradford's assay. Top and bottom oligonucleotides were labeled separately as per the manufacturer's protocol. The binding reactions contained 5 mg of nuclear extract, and buffers (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 1 mM dithiothreitol, 0.05% Nonidet P-40, 2.5% glycerol), 1 mg poly (dI:dC) and 20 fmole of biotinlabeled DNA. The sequences of NF-kB recognition site located on CXCR4 promoter used in electrophoretic mobility shift assay was as follows: top oligo, 5 0 -TCCCCTGGG CTTCCCAAGCC-3 0 and bottom oligo, 5 0 -GGCTTGGG AAGCCCAGGGGA-3 0 .
RT-PCR
Total cellular RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) and total RNA was prepared according to the manufacturer's instructions. In all, 1 mg of total RNA was reverse transcribed using ABI Reverse transcription kit (ABI Biosystems, Forest City, CA, USA). Primers specific to ANXA1, CXCR4 and uPA were used, and available upon request. Actin or GAPDH primers were used as an endogenous control. qPCR was performed using the SYBR Green PCR core reagents mix (Bio-Rad) Two replicates for each experimental point were performed and the results are expressed as the relative fold changes of the stimulated over the control, which was used as a calibrator.
Luciferase assays Cells were transfected once the confluence reached 40%. The cells were transiently transfected with 200 ng of NF-kBluciferase reporter plasmid (Stratagene, La Jolla, CA, USA), and 200 ng of Renilla plasmid in DMEM medium (without fetal bovine serum) with or without ANXA1 ASO (2 mg). The cells were incubated for 6-8 h, and then fresh DMEM/10% fetal bovine serum medium was added. After 36 h, the cells Annexin-1 constitutively activates NF-jB P Bist et al were treated with SDF1a (100 ng/ml) for 2 h. Luciferase activity was determined using the luciferase assay system with reporter lysis buffer from Promega (Madison, WI, USA). Briefly, the cells were harvested by scraping in 100 ml of reporter lysis buffer into a 1.5-ml microcentrifuge tube, vortex mixed for 15 s, centrifuged at 12 000 g for 30 s and supernatant cell lysates were collected. The results are expressed as relative NF-kB activity compared with controls after normalizing for Renilla activity and protein concentration.
Statistical data analysis Data were tested for normality and paired sets of data were compared using paired Student's t-test (two tailed). Comparisons between multiple treatment groups from the same experiment were made using one-way ANOVA. When significant differences were found between groups, Tukey's post hoc test was used to test significance. In all cases, Po0.05 was accepted as statistically significant.
